At present, various reports state that inhibition of PD-L1 and DNA methyl transferase-1 (DNMT1) significantly prevents the growth of Sorafenib resistant HCC cells in-vitro, and, thus, PD-1 and PD-L1 are considered novel valuable treatment options for Sorafenib resistant HCC [163] (Figure 4). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.